Zobrazeno 1 - 10
of 149
pro vyhledávání: '"Jean Sebastien FRENEL"'
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Recently many therapeutic classes have emerged in advanced hormone receptor-positive breast cancer, which is the leading cause of cancer death in women. In absence of visceral crisis, treatment relies on endocrine therapy combined with cyclin depende
Externí odkaz:
https://doaj.org/article/8b1b051acf4145d58d96075668e7bba1
Autor:
Paule Augereau, Anne Patsouris, Emmanuelle Bourbouloux, Carole Gourmelon, Sophie Abadie Lacourtoisie, Dominique Berton Rigaud, Patrick Soulié, Jean Sebastien Frenel, Mario Campone
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 9 (2017)
Endocrine therapy is the mainstay of treatment of estrogen-receptor-positive (ER+) breast cancer with an overall survival benefit. However, some adaptive mechanisms in the tumor emerge leading to the development of a resistance to this therapy. A bet
Externí odkaz:
https://doaj.org/article/ca4c0958e557434eae385369c0c3ecc5
Autor:
Mathilde Richard, Jean Sebastien FRENEL, Laurent Mathiot, Mario Campone, Mathilde Colombie, Marie Robert, Anne Patsouris, Frederic Bigot, Julie Gavard, Gwennan André-Grégoire, Laetitia Guevel
Publikováno v:
Cancer Research. 83:P3-11
CONTEXT: Endocrine therapy combined with CDK4/6 inhibitor is the standard frontline treatment for the vast majority of HR+/HER2- metastatic breast cancer (MBC) patients. Despite an overall survival benefit, patients eventually progress and mechanisms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0c822ba4ae8e7be3b3c65017d1d19a0
https://doi.org/10.1158/1538-7445.sabcs22-p3-11-09
https://doi.org/10.1158/1538-7445.sabcs22-p3-11-09
Autor:
Emeline, Colomba, Jérôme, Alexandre, Gwénaël, Le Teuff, Catherine, Genestie, Dahna, Coupez, Isabelle Ray, Coquard, Pierre Emmanuel, Brachet, Sixtine, de Percin, Christophe, Sajous, Michel, Fabbro, Nicolas, Delanoy, Florence, Joly, Jean Sebastien, Frenel, Patricia, Pautier, Alexandra, Leary
Publikováno v:
Gynecologic Oncology. 169:78-84
Around 15% of metastatic endometrial carcinoma (EC) are MMRd/MSI-H improving response to immune checkpoint inhibitors (ICI). So far, few data existed considering the chemotherapy (CT) sensitivity in MMRd/MSI-H EC, especially response to first-line pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09e1dcbaa6573f8d88a27ec68f4eef1c
https://doi.org/10.1016/j.ygyno.2022.11.029
https://doi.org/10.1016/j.ygyno.2022.11.029
Autor:
Sara A Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altintas, Jan-Willem Henning, Giuseppe Curigliano, José Manuel Perez-Garcia, Sung-Bae Kim, Vanessa Petry, Chiun-Sheng Huang, Wei Li, Jean-Sebastien Frenel, Silvia Antolin, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortés
Publikováno v:
The lancet : international edition
Background An improvement in progression-free survival was shown with trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer in the progression-free survival interim analysis of the DESTINY-Breast0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f34ca39bb4e6f5a2f1a4d78197528f6d
https://doi.org/10.1016/s0140-6736(22)02420-5
https://doi.org/10.1016/s0140-6736(22)02420-5
Autor:
Ivan Caramanna, Julie M de Kort, Alba A Brandes, Walter Taal, Michael Platten, Ahmed Idbaih, Jean Sebastien Frenel, Wolfgang Wick, Chandrakanth Jayachandran Preetha, Martin Bendszus, Philipp Vollmuth, Jaap C Reijneveld, Martin Klein
Publikováno v:
Neuro-Oncology Practice, 9(4), 310-316. Oxford University Press
Caramanna, I, de Kort, J M, Brandes, A A, Taal, W, Platten, M, Idbaih, A, Frenel, J S, Wick, W, Preetha, C J, Bendszus, M, Vollmuth, P, Reijneveld, J C & Klein, M 2022, ' Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma : Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101 ', Neuro-Oncology Practice, vol. 9, no. 4, pp. 310-316 . https://doi.org/10.1093/nop/npac022
Caramanna, I, de Kort, J M, Brandes, A A, Taal, W, Platten, M, Idbaih, A, Frenel, J S, Wick, W, Preetha, C J, Bendszus, M, Vollmuth, P, Reijneveld, J C & Klein, M 2022, ' Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma : Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101 ', Neuro-Oncology Practice, vol. 9, no. 4, pp. 310-316 . https://doi.org/10.1093/nop/npac022
Background In patients with recurrent glioblastoma, corticosteroids are frequently used to mitigate intracranial pressure and to improve patient neurological functioning. To date, in these patients, no systematic studies have been performed to assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb2c28b8c5f8c59785ef305e12fec0bb
http://www.scopus.com/inward/record.url?scp=85135757142&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85135757142&partnerID=8YFLogxK
Autor:
Damien Pouessel, Soléakhéna Ken, Valérie Gouaze-Andersson, Lucie Piram, Augustin Mervoyer, Delphine Larrieu-Ciron, Bastien Cabarrou, Amélie Lusque, Marie Robert, Jean-Sebastien Frenel, Emmanuelle Uro-Coste, Pascale Olivier, Muriel Mounier, Umberto Sabatini, Eduardo Hugo Sanchez, Mehdi Zouitine, Ahmad Berjaoui, Elizabeth Cohen-Jonathan Moyal
Publikováno v:
The Oncologist.
Background Hypofractionated stereotactic radiotherapy (hFSRT) is a salvage option for recurrent glioblastoma (GB) which may synergize anti-PDL1 treatment. This phase I study evaluated the safety and the recommended phase II dose of anti-PDL1 durvalum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f701ef28a3f7280268cd9b5610d1dde
https://doi.org/10.1093/oncolo/oyad095
https://doi.org/10.1093/oncolo/oyad095
Autor:
Johann S. de Bono, Gerhardt Attard, Nick Turner, Delila Gasi Tandefelt, Udai Banerji, Timothy A. Yap, Michael Ong, Joaquin Mateo, David Lorente, Roberta Ferraldeschi, Isaac Garcia-Murillas, Christophe Leux, Alan Smith, Daniel Nava-Rodrigues, Ines Figueiredo, Susana Miranda, Ruth Riisnaes, Nina Tunariu, Raquel Perez-Lopez, Desam Roda, Jane Goodall, Suzanne Carreira, Jean Sebastien Frenel
Supplementary Data 6: Monitoring of somatic genomic alterations in plasma during targeted therapy. Allele frequencies (AF) of identified mutations are represented on the left Y-axis while the sum of the target lesions on the CT scan, are represented
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9583de46c61b45a6dfc139a846854cf5
https://doi.org/10.1158/1078-0432.22461609
https://doi.org/10.1158/1078-0432.22461609
Autor:
Johann S. de Bono, Gerhardt Attard, Nick Turner, Delila Gasi Tandefelt, Udai Banerji, Timothy A. Yap, Michael Ong, Joaquin Mateo, David Lorente, Roberta Ferraldeschi, Isaac Garcia-Murillas, Christophe Leux, Alan Smith, Daniel Nava-Rodrigues, Ines Figueiredo, Susana Miranda, Ruth Riisnaes, Nina Tunariu, Raquel Perez-Lopez, Desam Roda, Jane Goodall, Suzanne Carreira, Jean Sebastien Frenel
Supplementary Data 1: Primers and probes for ddPCR assay Supplementary Data 2: Consort Diagram Supplementary Data 3: List of drugs Supplementary Data 4: Cross validation of PGM sequencing assay with ddPCR Supplementary Data 5: To test intra-run assay
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cfb6725909481b5f21ca21a1ff79d20
https://doi.org/10.1158/1078-0432.22461606.v1
https://doi.org/10.1158/1078-0432.22461606.v1
Autor:
Monika E. Hegi, Gianfranco Pesce, Benoit Lhermitte, Krisztian Homicsko, Kirsten Hopkins, Astrid Weyerbrock, Salvador Villa, Christine Marosi, Damien Ricard, Mario Campone, Jean-Sebastien Frenel, Vassilis Golfinopoulos, Patrick Roth, Roger Stupp, Michael Weller, Markus Kosch, Antje Wick, Marie-France Hamou, Alba A. Brandes, Jonathan Steuve, Martin J.B. Taphoorn, Martin J. van den Bent, Michael Platten, Pierre Bady, Thierry Gorlia, Wolfgang Wick
Suppl. Materials and Methods; 5 Suppl. Figures; 2 Suppl Tables and List of Participating Investigators Supplementary Figure S1. Definition of MGMT cut-off with a safety margin. Supplementary Figure S2. Comparison of Overall Survival in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7abf627cd68b404f5ebaed5b79d96a4c
https://doi.org/10.1158/1078-0432.22467896
https://doi.org/10.1158/1078-0432.22467896